| Literature DB >> 26380578 |
Shiva Marthandan1, Steffen Priebe2, Marco Groth1, Reinhard Guthke2, Matthias Platzer1, Peter Hemmerich1, Stephan Diekmann1.
Abstract
BACKGROUND: Rotenone inhibits the electron transfer from complex I to ubiquinone, in this way interfering with the electron transport chain in mitochondria. This chain of events induces increased levels of intracellular reactive oxygen species, which in turn can contribute to acceleration of telomere shortening and induction of DNA damage, ultimately resulting in aging. In this study, we investigated the effect of rotenone treatment in human fibroblast strains.Entities:
Year: 2015 PMID: 26380578 PMCID: PMC4572608 DOI: 10.1186/s12979-015-0038-8
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Fig. 1Growth curve and percentage of SA β-Gal positive cells in MRC-5 fibroblasts +/− rotenone treatment. a Growth curve of MRC-5 fibroblasts supplemented with 0.1 μM rotenone (green) compared to DMSO-treated controls (black). b Percentage of senescence associated SA β-Gal positive cells in 0.1 μM rotenone-treated young (PD 30) fibroblasts (green), compared to DMSO-treated controls (black). The arrows indicate the time points at which samples were collected and subjected to next generation sequencing and transcriptome analysis. The bars indicate the mean ± S.D. Values statistically different from their controls (t-test) are indicated with an asterix: ** p < 0.01, *** p < 0.001. c Percentage of SA β-Gal positive cells in 0.1 μM rotenone treated mid (PD 52) MRC-5 fibroblasts, compared to untreated controls. n = 3 in all cases
Fig. 2Growth curve and percentage of SA β-Gal positive cells in human foreskin fibroblasts +/− rotenone treatment. a Growth curve of HFF fibroblasts supplemented with 0.1 μM rotenone (green), compared to DMSO-treated controls (black). b Percentage of SA β-Gal positive cells in 0.1 μM rotenone treated young HFF fibroblasts (green), compared to DMSO-treated controls (black). The arrows indicate the time points at which samples were collected and subjected to next generation sequencing and transcriptome analysis. The bars indicate the mean ± S.D. Values statistically different from their controls (t-test) are indicated with an asterix: * p < 0.05, ** p < 0.01. n = 3 in all cases
Number of DEGs in primary human fibroblast strains + / - rotenone
| Fibroblast | PD+/− rotenone (R) | Number of DEGs |
|---|---|---|
| MRC-5 | PD38 − R to PD38 + R | 1 |
| PD42 − R to PD42 + R | 2086 | |
| PD48 − R to PD48 + R | 3527 | |
| PD52 − R to PD52 + R | 319 | |
| HFF | PD22 − R to PD22 + R | 1 |
| PD26 − R to PD26 + R | 4873 | |
| PD30 − R to PD30 + R | 8151 | |
| PD34 − R to PD34 + R | 6424 | |
| PD58 − R to PD58 + R | 5726 | |
| PD74 − R to PD74 + R | 60 |
The number of differentially expressed genes at different population doublings (PDs) in MRC-5 and HFFs supplemented with low dose (0.1 μM) rotenone compared to their corresponding controls (without rotenone but with DMSO). The stringency criteria applied for retrieving the DEGs included p < 0.05 and alignment with two statistical packages DESeq [68] and edgeR [69]
Fig. 3Variance and sample clustering of normalized transcriptome expression values. Principal component analysis (PCA) of MRC-5 (spheres) and HFF (triangles) cell strains of specific PDs (indicated by color) treated with (filled-in symbols) and without (empty symbols) rotenone. The triplicates are clearly grouped. One of the HFF control sample triplicates of PD34 and PD58 were outliers and were excluded for the analysis, thus only 2 symbols are displayed. The outliers could be attributed to batch effects [116] and their removal from analysis has previously been documented [117]. Interestingly, samples treated with rotenone at low PDs cluster more likely with low PDs which were not treated. Triplicates (identical symbols) are clustered indicating small experimental errors. For young (low PDs) and old (high PDs) MRC-5 and HFFs, triplicates with and without rotenone group together indicating little variance due to rotenone treatment. However, for some intermediate PDs, the triplicates with and without rotenone differ strongly indicating transcriptome differences due to rotenone treatment